ijcmcr International Journal of Clinical & Medical Case Reports 2834-250X International Journal of Clinical & Medical Case Reports Research The GLB, ANC, Bone Metastasis And PD-L1 Are Potential Predictive Markers For The Prognosis Of Advanced Or Metastatic NSCLC Treated With Immune Checkpoint Inhibitors Zheng Maike Department of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No.9 Beiguan Street, Tongzhou District, Beijing (101149), China Hu Mingming Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing (101149), China; Laboratory for Clinical Medicine, Capital Medical University, No.9 B... Liu Yanxia Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing (101149), China; Laboratory for Clinical Medicine, Capital Medical University, No.9 B... Li Xiaomi Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing (101149), China Wang Guirong Department of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No.9 Beiguan Street, Tongzhou District, Beijing (101149), China Zhang Tongmei Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing (101149), China; Laboratory for Clinical Medicine, Capital Medical University, No.9 B... Zhao Yan Department of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No.9 Beiguan Street, Tongzhou District, Beijing (101149), China 05 08 2024 6 1 20072024 29072024 © 2024 The Author(s). Published by International Journal of Clinical & Medical Case Reports. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0).

Immune checkpoint inhibitors (ICIs) hold a great promise in treatment of non-small cell lung cancer (NSCLC), while only a portion of patients benefited from the treatment, and others could not achieve optimal therapeutic effects from initial immunotherapy, even for those patients with PD-L1 tested positive. However, the clinical markers for the selection of patients who will benefit from ICIs treatment before hand are largely unknown. In this study, a retrospective analysis was conducted on baseline information of 144 patients with advanced/metastatic NSCLC who received ICIs treatment from the November of 2018 to the January of 2023 in Beijing Chest Hospital. We set up the nomogram model to make quantitative prediction for overall survival (OS) and progression-free survival (PFS) based on different variables, and established a scoring group chart as well as Decision curve analysis (DCA) to assess clinical benefits of ICIs in treatment of patients with advanced/metastatic NSCLC. We found that serum globulin (GLB)>26.6 (g/L) (HR=1.865, P=0.002), absolute neutrophil counts (ANC) (109/L)>5 (HR=2.146, P5 (HR=1.807, P=0.008), bone metastasis (HR=1.651, P=0.002), and PD-L1 Negative (HR=2.432,P=0.032) were independent factors affecting the survival of NSCLC patients. These data show that patients with the four favorable factors had better survivals. Thus, in patients with advanced/metastatic NSCLC receiving ICIs treatment, the GLB, ANC, bone metastasis, and PD-L1 may serve as useful predictive markers for the prognosis of NSCLC patients with ICIs treatment.

 Prognosis Glb Anc Bone Metastasis Icis Advanced Nsclc